The U.S. Food and Drug Administration has approved Zepatier with or without ribavirin for the treatment of chronic Hepatitis C genotypes 1 and 4 infections in adult patients.
Tag Archive for: FDA
A network building capacity to prevent, manage and treat hepatitis B and C in NYC
Upcoming Training Events
- There are no upcoming events.
News & Recent Posts
- Job | Hep C Clinical Program Manager @ NYC Health + Hospitals September 17, 2024
- Opportunity | Harm Reduction Peer Academy (Deadline September 27, 2024) September 3, 2024
- Job | Nurse Practitioner @ Mount Sinai Health System August 27, 2024
- Job | Hep C Patient Navigator @ Bedford-Stuyvesant Family Health Center August 27, 2024
- NYC Hep C Task Force Meeting Highlights | 07-24-2024 August 8, 2024
- Communications Committee Meeting Highlights | 6-20-2024 August 6, 2024
- NYC Hep B Coalition Meeting Highlights | 7-10-2024 July 23, 2024
- NYC Hep C Task Force Meeting Highlights | 03-20-2024 June 24, 2024